VANCOUVER, British Columbia, May 20, 2004 (PRIMEZONE) -- ProtoKinetix Inc. (OTCBB:PKTX) announces today that it has received a report from the Georges Pompidou Hospital in Paris on the first 40 patients studied with RECAF(TM) on mammary tissue. The report states that there is a constant expression of RECAF on tumoral epithelial cells, mainly strong expression."
Based on these results, the Georges Pompidou Hospital will be proceeding to test the RECAF antibody on additional cancers. At this time, the ProtoKinetix Scientific Advisory Board is satisfied that these third-party validation results have confirmed the presence of the RECAF receptor site on cancer cells. ProtoKinetix will commence immediately with the design of a research program towards the development of a therapeutic agent.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President